Last reviewed · How we verify
placedo
placedo is a Small molecule drug developed by Xiangya Hospital of Central South University. It is currently in Phase 2 development.
Placedo is a census-designated place in Victoria County, Texas, with a population of 625 as of the 2020 census. There is no direct information linking the term "placedo" to a medical treatment or intervention, but it has been used as a control group in a clinical trial studying the efficacy of sulforaphane for depression.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | placedo |
|---|---|
| Sponsor | Xiangya Hospital of Central South University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Kui-Yuan Chewable Tablets in Patients With Hyperuricemia (PHASE4)
- Efficacy and Safety of Colquhounia Root Tablet in Patients With Rheumatoid Arthritis (PHASE4)
- Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After STEMI (PHASE2, PHASE3)
- A 12-weeks Study to Evaluate Sulforaphane in the Treatment of Depression (PHASE2)
- Effects of Sulforaphane on Cognitive Function in Patients With Frontal Brain Damage (PHASE2)
- Investigation of Supplemental L-alanine in the Management of Dietary Fructose Intolerance (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placedo CI brief — competitive landscape report
- placedo updates RSS · CI watch RSS
- Xiangya Hospital of Central South University portfolio CI
Frequently asked questions about placedo
What is placedo?
Who makes placedo?
What development phase is placedo in?
Related
- Manufacturer: Xiangya Hospital of Central South University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing